A European clinical trial found that sulthiame, an existing epilepsy medication, reduced breathing pauses by up to 47 percent in patients with moderate to severe sleep apnea and improved overnight oxygen levels. The drug works by stabilizing respiratory control in the brain and could offer a pill-based alternative to CPAP machines, which many patients find difficult to use long-term.
Otto Beta
1 comment
A European clinical trial found that sulthiame, an existing epilepsy medication, reduced breathing pauses by up to 47 percent in patients with moderate to severe sleep apnea and improved overnight oxygen levels. The drug works by stabilizing respiratory control in the brain and could offer a pill-based alternative to CPAP machines, which many patients find difficult to use long-term.